Aspire Biopharma Files provisional patent application With U.S. Patent and Trademark Office Titled 'A Sublingual Powder Formulation of Ondansetron and Methods of Use Thereof'

Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO). The application, titled "A Sublingual Powder Formulation of Ondansetron and Methods of Use Thereof," marks the first-ever sublingual powder delivery system for ondansetron-the active ingredient in Zofran®. Aspire's formulation is designed to provide rapid relief for patients suffering from nausea and vomiting induced by chemotherapy, radiation, or surgery.